1887

Abstract

Serum antibody levels can be used to measure the humoral immune response against human papillomaviruses (HPV). We developed and validated a rapid, technically simple and relatively inexpensive multiplex non-competitive Luminex-based immunoassay (ncLIA) to measure total IgG antibody levels against four HPV types. For the assay’s solid phase, virus-like particles (VLPs) of HPV6, 11, 16 and 18 were bound to heparin-coated beads. HPV serum antibody levels binding to the VLPs were quantified using a phycoerithrin-conjugated secondary polyclonal donkey anti-human IgG antibody. Standardization and validation of the ncLIA were performed using 96 paired serum and genital samples from participants in the HITCH cohort study, including young women (aged 18–24 years) and their male sexual partners (aged 18+) in Montreal, Canada. Results from the ncLIA were compared to a validated Luminex immunoassay from PPD laboratories using Pearson’s correlation coefficients, receiver operating characteristic curves and logistic regression. Our assay had good inter- and intra-assay variability. The correlation of serum antibody levels between the ncLIA and validation assay was highest for HPV16 and HPV11 (=0.90), followed by HPV6 (=0.86) and HPV18 (=0.67). The ncLIA was better able to predict HPV DNA positivity in genital samples than the validation assay for HPV16 [area under the curve (AUC) 0.65 versus 0.52, =0.001] and HPV18 [AUC 0.71 versus 0.57, =0.024]. AUCs for HPV6 and HPV11 were similar between the two assays (0.70 versus 0.71, =0.59, and 0.88 versus 0.96, =0.08, respectively). The developed ncLIA is useful for measuring total IgG antibody response following natural infection or vaccination against four HPV VLPs included in the quadrivalent vaccine.

Funding
This study was supported by the:
  • Tier 2 Canada Research Chair in Sexually Transmitted Infection Prevention
    • Principle Award Recipient: BurchellAnn N.
  • Réseau FRQS SIDA-MI
    • Principle Award Recipient: CoutléeFrançois
  • Merck & Co.
    • Principle Award Recipient: CouillardMichel
  • Abbott Laboratories Canada
    • Principle Award Recipient: CouillardMichel
  • The Ministry of Health and Social Services of Quebec, QC, Canada
    • Principle Award Recipient: CouillardMichel
  • Canadian Institutes of Health Research
    • Principle Award Recipient: WissingMichel D.
  • National Institutes of HealthR01AI073889
    • Principle Award Recipient: FrancoEduardo L.
  • Canadian Institutes of Health ResearchCRN-83320
    • Principle Award Recipient: FrancoEduardo L.
  • Canadian Institutes of Health ResearchMOP-68893
    • Principle Award Recipient: FrancoEduardo L.
Loading

Article metrics loading...

/content/journal/jgv/10.1099/jgv.0.001610
2021-05-27
2021-09-18
Loading full text...

Full text loading...

References

  1. Franco EL, de Sanjose S, Broker TR, Stanley MA, Chevarie-Davis M et al. Human papillomavirus and cancer prevention: gaps in knowledge and prospects for research, policy, and advocacy. Vaccine 2012; 30:F175–182 [View Article]
    [Google Scholar]
  2. Plummer M, de Martel C, Vignat J, Ferlay J, Bray F et al. Global burden of cancers attributable to infections in 2012: A synthetic analysis. Lancet Glob Health 2016; 4:e609–16 [View Article]
    [Google Scholar]
  3. Joura EA, Giuliano AR, Iversen OE, Bouchard C, Mao C et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med 2015; 372:711–723 [View Article][PubMed]
    [Google Scholar]
  4. Buck CB, Day PM, Trus BL. The papillomavirus major capsid protein L1. Virology 2013; 445:169–174 [View Article][PubMed]
    [Google Scholar]
  5. Schiller JT, Castellsague X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 2012; 30:F123–138 [View Article]
    [Google Scholar]
  6. Lin SW, Ghosh A, Porras C, Markt SC, Rodriguez AC et al. HPV16 seropositivity and subsequent HPV16 infection risk in a naturally infected population: comparison of serological assays. PloS one 2013; 8:e53067 [View Article][PubMed]
    [Google Scholar]
  7. Hernandez BY, Ton T, Shvetsov YB, Goodman MT, Zhu X. Human papillomavirus (HPV) L1 and L1-L2 virus-like particle-based multiplex assays for measurement of HPV virion antibodies. Clin Vaccine Immunol 2012; 19:1348–1352 [View Article][PubMed]
    [Google Scholar]
  8. Wideroff L, Schiffman MH, Nonnenmacher B, Hubbert N, Kirnbauer R et al. Evaluation of seroreactivity to human papillomavirus type 16 virus-like particles in an incident case-control study of cervical neoplasia. J Infect Dis 1995; 172:1425–1430 [View Article][PubMed]
    [Google Scholar]
  9. Pastrana DV, Buck CB, Pang YY, Thompson CD, Castle PE et al. Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology 2004; 321:205–216 [View Article][PubMed]
    [Google Scholar]
  10. Buck CB, Pastrana DV, Lowy DR, Schiller JT. Generation of HPV pseudovirions using transfection and their use in neutralization assays. Methods Mol Med 2005; 119:445–462 [View Article][PubMed]
    [Google Scholar]
  11. Opalka D, Matys K, Bojczuk P, Green T, Gesser R et al. Multiplexed serologic assay for nine anogenital human papillomavirus types. Clin Vaccine Immunol 2010; 17:818–827 [View Article][PubMed]
    [Google Scholar]
  12. Nie J, Huang W, Wu X, Wang Y. Optimization and validation of a high throughput method for detecting neutralizing antibodies against human papillomavirus (HPV) based on pseudovirons. J Med Virol 2014; 86:1542–1555 [View Article][PubMed]
    [Google Scholar]
  13. Dias D, Van Doren J, Schlottmann S, Kelly S, Puchalski D et al. Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18. Clin Diagn Lab Immunol 2005; 12:959–969 [View Article][PubMed]
    [Google Scholar]
  14. Roberts C, Green T, Hess E, Matys K, Brown MJ et al. Development of a human papillomavirus competitive luminex immunoassay for 9 HPV types. Hum Vaccin Immunother 2014; 10:2168–2174 [View Article][PubMed]
    [Google Scholar]
  15. Dessy FJ, Giannini SL, Bougelet CA, Kemp TJ, David MP et al. Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine. Hum Vaccin 2008; 4:425–434 [View Article][PubMed]
    [Google Scholar]
  16. Robbins HA, Kemp TJ, Porras C, Rodriguez AC, Schiffman M et al. Comparison of antibody responses to human papillomavirus vaccination as measured by three assays. Front Oncol 2014; 3:328 [View Article][PubMed]
    [Google Scholar]
  17. Panicker G, Rajbhandari I, Gurbaxani BM, Querec TD, Unger ER. Development and evaluation of multiplexed immunoassay for detection of antibodies to HPV vaccine types. J Immunol Methods 2015; 417:107–114 [View Article][PubMed]
    [Google Scholar]
  18. Waterboer T, Sehr P, Michael KM, Franceschi S, Nieland JD et al. Multiplex human papillomavirus serology based on in situ-purified glutathione s-transferase fusion proteins. Clin Chem 2005; 51:1845–1853 [View Article][PubMed]
    [Google Scholar]
  19. Robbins HA, Waterboer T, Porras C, Kemp TJ, Pawlita M et al. Immunogenicity assessment of HPV16/18 vaccine using the glutathione S-transferase L1 multiplex serology assay. Hum Vaccin Immunother 2014; 10:2965–2974 [View Article][PubMed]
    [Google Scholar]
  20. Faust H, Knekt P, Forslund O, Dillner J. Validation of multiplexed human papillomavirus serology using pseudovirions bound to heparin-coated beads. J Gen Virol 2010; 91:1840–1848 [View Article][PubMed]
    [Google Scholar]
  21. Gilca V, Sauvageau C, Boulianne N, De Serres G, Couillard M et al. Immunogenicity of quadrivalent HPV and combined hepatitis A and B vaccine when co-administered or administered one month apart to 9–10 year-old girls according to 0–6 month schedule. Human Vaccin Immunother 2014; 10:23–30
    [Google Scholar]
  22. Gilca V, Sauvageau C, Boulianne N, De Serres G, Crajden M et al. The effect of a booster dose of quadrivalent or bivalent HPV vaccine when administered to girls previously vaccinated with two doses of quadrivalent HPV vaccine. Hum Vaccin Immunother 2015; 11:732–738 [View Article][PubMed]
    [Google Scholar]
  23. Zahreddine M, Mayrand MH, Therrien C, Trevisan A, Dagenais C et al. Antibodies to human papillomavirus types 6, 11, 16 and 18: Vertical transmission and clearance in children up to two years of age. EClinicalMedicine 2020; 21:100334 [View Article][PubMed]
    [Google Scholar]
  24. Buck CB, Pastrana DV, Lowy DR, Schiller JT. Efficient intracellular assembly of papillomaviral vectors. J Virol 2004; 78:751–757 [View Article][PubMed]
    [Google Scholar]
  25. Buck CB, Thompson CD. Production of papillomavirus-based gene transfer vectors. Juan S B. eds In Current protocols in Cell Biology / Editorial Board 2007
    [Google Scholar]
  26. El-Zein M, Coutlée F, Tellier PP, Roger M, Franco EL et al. Human papillomavirus infection and transmission among couples through heterosexual activity (HITCH) cohort study: Protocol describing design, methods, and research goals. JMIR Res Protoc 2019; 8:e11284 [View Article][PubMed]
    [Google Scholar]
  27. Coutlée F, Rouleau D, Petignat P, Ghattas G, Kornegay JR et al. Enhanced detection and typing of human papillomavirus (HPV) DNA in anogenital samples with PGMY primers and the Linear array HPV genotyping test. J Clin Microbiol 2006; 44:1998–2006 [View Article]
    [Google Scholar]
  28. Opalka D, Lachman CE, MacMullen SA, Jansen KU, Smith JF et al. Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assay. Clin Diagn Lab Immunol 2003; 10:108–115 [View Article][PubMed]
    [Google Scholar]
  29. Kovaleva A, Alberts CJ, Waterboer T, Michel A, Snijder MB et al. A cross-sectional study on the concordance between vaginal HPV DNA detection and type-specific antibodies in a multi-ethnic cohort of women from Amsterdam, the Netherlands - the HELIUS study. BMC Infect Dis 2016; 16:502 [View Article][PubMed]
    [Google Scholar]
  30. Youden WJ. Index for rating diagnostic tests. Cancer 1950; 3:32–35 [View Article][PubMed]
    [Google Scholar]
  31. FUTUREIIStudyGroup Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356:1915–1927 [View Article][PubMed]
    [Google Scholar]
  32. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007; 356:1928–1943 [View Article][PubMed]
    [Google Scholar]
  33. Herrero R, Wacholder S, Rodriguez AC, Solomon D, Gonzalez P et al. Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: a community-based randomized clinical trial in Guanacaste, Costa Rica. Cancer Discov 2011; 1:408–419 [View Article][PubMed]
    [Google Scholar]
  34. Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland SM et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012; 13:89–99 [View Article][PubMed]
    [Google Scholar]
  35. Beachler DC, Jenkins G, Safaeian M, Kreimer AR, Wentzensen N. Natural acquired immunity against subsequent genital human papillomavirus infection: a systematic review and meta-analysis. J Infect Dis 2016; 213:1444–1454 [View Article][PubMed]
    [Google Scholar]
  36. Carter JJ, Wipf GC, Madeleine MM, Schwartz SM, Koutsky LA et al. Identification of human papillomavirus type 16 L1 surface loops required for neutralization by human sera. J Virol 2006; 80:4664–4672 [View Article][PubMed]
    [Google Scholar]
  37. Brown DR, Garland SM, Ferris DG, Joura E, Steben M et al. The humoral response to Gardasil over four years as defined by total IgG and competitive Luminex immunoassay. Hum Vaccin 2011; 7:230–238 [View Article][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/jgv.0.001610
Loading
/content/journal/jgv/10.1099/jgv.0.001610
Loading

Data & Media loading...

Supplements

Supplementary material 1

PDF

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error